University of Virginia-Main Campus · Biomedical EngineeringChagas Disease Nanotherapy Lab
Evan Alexander Scott · Charlottesville, Virginia
Research Focus
Evan Alexander Scott's lab at the University of Virginia focuses on developing innovative nanotherapeutic strategies to tackle chronic Chagas disease, particularly its associated heart condition, chronic Chagas cardiomyopathy (CCC). The lab aims to create treatments that not only reduce inflammation and cardiac damage but also target the parasite's reservoirs within the body. By optimizing drug delivery systems and minimizing toxicity, the lab seeks to provide effective therapies for patients battling this neglected tropical disease.
Chagas diseasenanotherapycardiomyopathydrug deliveryanti-inflammatoryparasite reservoirsBenznidazoleChagas drug treatmentthiophenetolerogenic therapy
Research Aims
5AIM 01Develop nanotherapies that safely treat chronic Chagas cardiomyopathy without reactivating Trypanosoma cruzi.
AIM 02Target and eliminate parasite reservoirs, especially in adipose tissue.
AIM 03Create new thiophene-based nanotherapy to combat Benznidazole-resistant T. cruzi strains.
AIM 04Assess the efficacy of combination therapies across different clinical strains of T. cruzi.
AIM 05Optimize drug delivery systems for localized treatment in heart tissues.
Skills the Lab Values
Nanocarrier drug deliveryIn vitro assaysTargeted drug deliveryAnimal modelsInjection techniquesBiological assay developmentImmunological assaysSynthesis of nanomaterialsTherapeutic formulationCollaboration with international research teams
Output against the department
Publications161bottom 36% of dept.382nd of 595
this lab
most publishedleast published
Citations3.4kbottom 26% of dept.440th of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.